BFG
SGMO

Bleakley Financial Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bleakley Financial Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,248
Closed -$18K – 973
2023
Q1 		$18K Buy
+10,248
New +$29.2K ﹤0.01% 899

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleakley Financial Group's SGMO Position: Q2 2023 in Review

Bleakley Financial Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 10,248 shares — an estimated $18K sold.

Bleakley Financial Group first reported a position in SGMO in Q1 2023 and held it in 1 quarter. The position peaked at $18K in Q1 2023. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Bleakley Financial Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Bleakley Financial Group sold 10,248 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $18K.
  • Bleakley Financial Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2023 and held it in 1 quarter.
  • Bleakley Financial Group's SANGAMO THERAPEUTICS INC position peaked at $18K in Q1 2023.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Bleakley Financial Group's 13F filing for Q2 2023, filed 14 Aug 2023.